AGAFAmerican General Auto Finance (American International Group, Inc.; Evansville, IN; est. 1920)
References in periodicals archive ?
Brill, MD AGAF CHCQM, Chief Medical Officer, Predictive Health, LLC
Loren Laine, MD, AGAF, Yale School of Medicine and VA Connecticut Healthcare System, West Haven, CT, who led the consensus group, said the process for creating these recommendations included representatives of all stakeholder groups -- endoscopists, pathologists, nurses, IBD experts, patients and more-in an open and transparent process.
This line of research promises not just scientific knowledge but could lead to treatments to improve the lives of patients with Crohn's disease and ulcerative colitis," said Martin Brotman, MD, AGAF, Chair, AGA Research Foundation.
Brill, MD, AGAF, CHCQM, Board member and Chair of the Continuing Education Committee noted, "In an era of accountability, Health Care Quality and Management (HCQM) certification demonstrates professionals have the practical knowledge and tools that can reduce medical errors, ensure patient safety, eliminate waste and unnecessary services, coordinate and avoid potentially harmful delays in care.
Floch , MD, MACG, FACP, AGAF, is a Clinical Professor of Medicine at Yale University School of Medicine and was Director of Ambulatory GI Services in the Digestive Disease Section at Yale from 2005-2011.
Hecht, MD, MS, AGAF, president of the AGA Institute, which administers practice, research and education programs of the organization.
Brill, MD, AGAF, FASGE, FACG, CHCQM, Chief Medical Officer, Predictive Health, LLC; Dogu Celebi, MD, MPH, Senior Vice President Clinical Affairs, Ingenix; Ian Duncan, FSA, MAAA, President, Solucia Inc.
Allen, MD, MBA, AGAF, Clinical Practice & Quality Management Committee Chair, AGA Institute.
Chey, MD, AGAF, FACG, FACP of the University of Michigan and Paul Moayyedi, BSc, MB ChB, PhD, MPH, FRCP, FRCPC, FACG of McMaster University.
William Chey, MD, AGAF, FACG, FACP, Professor of Medicine at the University of Michigan Health System, said, "These results demonstrated the potential for naloxegol, if approved, to be a new treatment option as the studies showed rapid and sustained improvement for these patients, without compromising their pain management over the course of the trials.
Brian Fennerty, MD, AGAF, professor of medicine at Oregon Health Sciences University and principal investigator for the STAR Registry.